Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JBI-802 in MPN and MDS/MPN
NCT07612280Phase 2Recruiting
- Sponsor
- Jubilant Therapeutics Inc.
- Start
- Oct 2024
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of JBI-802 in myeloproliferative neoplasms (MPN), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), sponsored by Jubilant Therapeutics Inc.. Started Oct 2024; status: recruiting.
02
Drugs
JBI-802
03
Conditions
myeloproliferative neoplasms (MPN)myelodysplastic/myeloproliferative neoplasms (MDS/MPN)essential thrombocythemia (ET)polycythemia vera (PV)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07612280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07612280.